MapLight Therapeutics (MPLT) Profit After Tax (2024 - 2025)
MapLight Therapeutics recorded quarterly Profit After Tax of -$79.5 million in Q4 2025, down 170.41% quarter-over-quarter from -$29.4 million in Q3 2025, and down 274.71% year-over-year from $45.5 million in Q4 2024.
MapLight Therapeutics' Profit After Tax history runs 2 years deep, the most recent figure standing at -$79.5 million for Q4 2025.
- In Q4 2025, Profit After Tax fell 274.71% year-over-year to -$79.5 million; the TTM figure through Dec 2025 stood at -$149.2 million (changed N/A YoY), while the FY2025 annual figure was -$161.2 million, down 107.72% from the prior year.
- Profit After Tax came in at -$79.5 million for Q4 2025 at MapLight Therapeutics, down from -$29.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$19.0 million in Q3 2024 to a low of -$79.5 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | -79.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.55 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Dec 31, 2024 | -21.23 Mn |
| Sep 30, 2024 | -19.02 Mn |